ATC Group: P01BF Artemisinin and derivatives, combinations

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of P01BF in the ATC hierarchy

Level Code Title
1 P Antiparasitic products, insecticides and repellents
2 P01 Antiprotozoals
3 P01B Antimalarials
4 P01BF Artemisinin and derivatives, combinations

Group P01BF contents

Code Title
P01BF01 Artemether and lumefantrine
P01BF02 Artesunate and mefloquine
P01BF03 Artesunate and amodiaquine
P01BF04 Artesunate, sulphamethopyrazine and pyrimethamine
P01BF05 Artenimol and piperaquine
P01BF06 Artesunate and pyronaridine
P01BF07
P01BF08
P01BF09

Active ingredients in P01BF

Active Ingredient Description
Artemether and Lumefantrine

Artemether/lumefantrine fixed-dose combination comprises a fixed ratio of 1:6 parts of artemether and lumefantrine, respectively. The site of antiparasitic action of both components is the food vacuole of the malarial parasite, where they are thought to interfere with the conversion of haem, a toxic intermediate produced during haemoglobin breakdown, to the nontoxic haemozoin, malaria pigment. Both artemether and lumefantrine have a secondary action involving inhibition of nucleic acid and protein synthesis within the malarial parasite.

Artenimol and Piperaquine

Artenimol is able to reach high concentrations within the parasitized erythrocytes. Its endoperoxide bridge is thought to be essential for its antimalarial activity, causing free-radical damage to parasite membrane systems. The exact mechanism of action of piperaquine is unknown, but it likely mirrors that of chloroquine, a close structural analogue. Piperaquine is a bisquinoline, and this class has shown good antimalarial activity against chloroquineresistant Plasmodium strains in vitro.

Related product monographs

Title Information Source Document Type  
COARTEM Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
EURARTESIM Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
RIAMET Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC